Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)

Nenhuma Miniatura disponível
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
Autores
MOREIRA, Rodrigo Oliveira
VALERIO, Cynthia Melissa
VILLELA-NOGUEIRA, Cristiane Alves
GERCHMAN, Fernando
GODOY-MATAS, Amelio Fernando
OLIVEIRA, Ricardo de Andrade
MELLO, Carlos Eduardo Brandao
ALVARES-DA-SILVA, Mario Reis
Citação
ARCHIVES OF ENDOCRINOLOGY METABOLISM, v.67, article ID e230123, 23p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on NAFLD. In the absence of studies on a certain topic or when the quality of the study was not adequate, the opinion of experts was adopted. Classes of Recommendation and Levels of Evidence were determined using prespecified criteria. Results: Based on the literature review, 48 specific recommendations were elaborated, including 11 on screening and diagnosis, 9 on follow-up, 14 on nonpharmacologic treatment, and 14 on pharmacologic and surgical treatment. Conclusions: A literature search allowed the development of evidence-based guidelines on the screening, diagnosis, treatment, and follow-up of MASLD in individuals with overweight or obesity.
Palavras-chave
Clinical guidelines, overweight, obesity, non-alcoholic fatty liver disease, metabolic dysfunction-associated steatotic liver disease
URI
https://observatorio.fm.usp.br/handle/OPI/58885
Referências
  1. Abdelmalek MF, 2010, HEPATOLOGY, V51, P1961, DOI 10.1002/hep.23535
  2. Abenavoli L, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080870
  3. Agarwal L, 2021, SURG OBES RELAT DIS, V17, P525, DOI 10.1016/j.soard.2020.11.004
  4. Ahn JS, 2017, ALIMENT PHARM THER, V45, P345, DOI 10.1111/apt.13866
  5. Ajmera VH, 2020, HEPATOLOGY, V71, P849, DOI 10.1002/hep.30974
  6. Alqahtani SA, 2021, OBES SURG, V31, P2002, DOI 10.1007/s11695-020-04996-1
  7. Aminian A, 2021, JAMA-J AM MED ASSOC, V326, P2031, DOI 10.1001/jama.2021.19569
  8. Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043
  9. Are VS, 2020, AM J GASTROENTEROL, V115, P1849, DOI 10.14309/ajg.0000000000000911
  10. Avcu A, 2021, TURK J GASTROENTEROL, V32, P466, DOI 10.5152/tjg.2021.20498
  11. Baker CJ, 2021, J DIABETES, V13, P63, DOI 10.1111/1753-0407.13086
  12. Bazerbachi F, 2021, CLIN GASTROENTEROL H, V19, P146, DOI 10.1016/j.cgh.2020.04.068
  13. Berzigotti A, 2021, J HEPATOL, V75, P659, DOI 10.1016/j.jhep.2021.05.025
  14. Bril F, 2015, LIVER INT, V35, P2139, DOI 10.1111/liv.12840
  15. Buzzetti E, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013156.pub2
  16. Cao YT, 2022, ECLINICALMEDICINE, V51, DOI 10.1016/j.eclinm.2022.101547
  17. Castera L, 2020, LIVER INT, V40, P77, DOI 10.1111/liv.14347
  18. Caussy C, 2018, HEPATOLOGY, V68, P763, DOI 10.1002/hep.29797
  19. Caussy C, 2018, CLIN GASTROENTEROL H, V16, P1974, DOI 10.1016/j.cgh.2017.10.037
  20. López IC, 2017, OBES SURG, V27, P2347, DOI 10.1007/s11695-017-2606-9
  21. Center for Drug Evaluation and Research (CDER), 2019, Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: Developing drugs for treatment
  22. Chalasani N, 2019, LIVER INT, V39, P924, DOI 10.1111/liv.13974
  23. Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
  24. Chang Y, 2019, HEPATOLOGY, V69, P64, DOI 10.1002/hep.30170
  25. Chang Y, 2016, AM J GASTROENTEROL, V111, P1133, DOI 10.1038/ajg.2016.178
  26. Chen YP, 2019, CLIN NUTR, V38, P2552, DOI 10.1016/j.clnu.2018.11.030
  27. Chiu S, 2014, EUR J CLIN NUTR, V68, P416, DOI 10.1038/ejcn.2014.8
  28. Coelho FD, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3413
  29. Cotrim HP, 2016, CLINICS, V71, P281, DOI 10.6061/clinics/2016(05)07
  30. Dai YZ, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.622589
  31. Silva MBDE, 2021, OBES SURG, V31, P2762, DOI 10.1007/s11695-021-05412-y
  32. Drolz A, 2021, INT J OBESITY, V45, P2197, DOI 10.1038/s41366-021-00881-8
  33. Duell PB, 2022, ARTERIOSCL THROM VAS, V42, pE168, DOI 10.1161/ATV.0000000000000153
  34. Dulai PS, 2017, HEPATOLOGY, V65, P1557, DOI 10.1002/hep.29085
  35. Dunn W, 2012, J HEPATOL, V57, P384, DOI 10.1016/j.jhep.2012.03.024
  36. Eddowes PJ, 2019, GASTROENTEROLOGY, V156, P1717, DOI 10.1053/j.gastro.2019.01.042
  37. Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368
  38. Ekstedt M, 2009, SCAND J GASTROENTERO, V44, P366, DOI 10.1080/00365520802555991
  39. Eslam M, 2020, J HEPATOL, V73, P202, DOI 10.1016/j.jhep.2020.03.039
  40. Faludi AA, 2017, ARQ BRAS CARDIOL, V109, P1, DOI 10.5935/abc.20170188
  41. Gepner Y, 2019, J HEPATOL, V71, P379, DOI 10.1016/j.jhep.2019.04.013
  42. Gu JL, 2019, EUR RADIOL, V29, P3564, DOI 10.1007/s00330-019-06072-4
  43. Guveli H, 2021, HEPATOL FORUM, V2, P97, DOI 10.14744/hf.2021.2021.0014
  44. Hagstroem H, 2024, BIOCATAL AGR BIOTECH, V56, pE76, DOI 10.1016/j.jhep.2023.08.026
  45. Hagström H, 2017, J HEPATOL, V67, P1265, DOI 10.1016/j.jhep.2017.07.027
  46. Hart CL, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1240
  47. Hartman ML, 2020, DIABETES CARE, V43, P1352, DOI 10.2337/dc19-1892
  48. Haufe S, 2013, DIABETES CARE, V36, P3786, DOI 10.2337/dc13-0102
  49. Hayat U, 2021, ANN HEPATOL, V20, DOI 10.1016/j.aohep.2020.08.071
  50. Hernaez R, 2011, HEPATOLOGY, V54, P1082, DOI 10.1002/hep.24452
  51. Hsu C, 2019, CLIN GASTROENTEROL H, V17, P630, DOI 10.1016/j.cgh.2018.05.059
  52. Huang YS, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000031437
  53. Izzy M, 2021, GASTROENTEROL REP, V9, P252, DOI 10.1093/gastro/goaa057
  54. Jafarov F, 2020, EUR J GASTROEN HEPAT, V32, P642, DOI 10.1097/MEG.0000000000001573
  55. Jalali M, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104799
  56. Jan A, 2015, OBES SURG, V25, P1518, DOI 10.1007/s11695-015-1727-2
  57. Jarvis H, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003100
  58. Jensen MD, 2014, J AM COLL CARDIOL, V63, P2985, DOI 10.1016/j.jacc.2013.11.004
  59. Kanwal F, 2018, GASTROENTEROLOGY, V155, P1828, DOI 10.1053/j.gastro.2018.08.024
  60. Katsagoni CN, 2017, METABOLISM, V68, P119, DOI 10.1016/j.metabol.2016.12.006
  61. Kaya E, 2020, GUT LIVER, V14, P486, DOI 10.5009/gnl19173
  62. Kennedy OJ, 2016, ALIMENT PHARM THER, V43, P562, DOI 10.1111/apt.13523
  63. Kim Y, 2019, LIVER INT, V39, P1884, DOI 10.1111/liv.14184
  64. Kleiner DE, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12565
  65. Koutoukidis DA, 2021, METABOLISM, V115, DOI 10.1016/j.metabol.2020.154455
  66. Kwo PY, 2017, AM J GASTROENTEROL, V112, P18, DOI 10.1038/ajg.2016.517
  67. Kwon HK, 2014, LIVER INT, V34, P129, DOI 10.1111/liv.12230
  68. Lassailly G, 2020, GASTROENTEROLOGY, V159, P1290, DOI 10.1053/j.gastro.2020.06.006
  69. Lazo M, 2010, DIABETES CARE, V33, P2156, DOI 10.2337/dc10-0856
  70. Lee YM, 2012, GASTROINTEST ENDOSC, V76, P756, DOI 10.1016/j.gie.2012.05.023
  71. Lee Y, 2019, CLIN GASTROENTEROL H, V17, P1040, DOI 10.1016/j.cgh.2018.10.017
  72. Li Y, 2013, BIOMED REP, V1, P57, DOI 10.3892/br.2012.18
  73. Ma JT, 2015, J HEPATOL, V63, P462, DOI 10.1016/j.jhep.2015.03.032
  74. Ma XF, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-1165-z
  75. Maersk M, 2012, AM J CLIN NUTR, V95, P283, DOI 10.3945/ajcn.111.022533
  76. Magid DJ, 2020, CIRCULATION, V142, pS358, DOI 10.1161/CIR.0000000000000898
  77. Mantovani A, 2020, DIABETES METAB, V46, P427, DOI 10.1016/j.diabet.2019.12.007
  78. Mantovani A, 2021, LANCET GASTROENTEROL, V6, P903, DOI 10.1016/S2468-1253(21)00308-3
  79. Mantovani A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052350
  80. Mantovani A, 2021, METABOLITES, V11, DOI 10.3390/metabo11020073
  81. Marchesini G, 2016, J HEPATOL, V64, P1388, DOI 10.1016/j.jhep.2015.11.004
  82. Marengo A, 2016, ANNU REV MED, V67, P103, DOI 10.1146/annurev-med-090514-013832
  83. Mofrad P, 2003, HEPATOLOGY, V37, P1286, DOI 10.1053/jhep.2003.50229
  84. Moolla A, 2019, FRONTLINE GASTROENTE, V10, P337, DOI 10.1136/flgastro-2018-101155
  85. Mottin CC, 2004, OBES SURG, V14, P635, DOI 10.1381/096089204323093408
  86. Mozes FE, 2022, GUT, V71, P1006, DOI 10.1136/gutjnl-2021-324243
  87. Musso G, 2017, JAMA INTERN MED, V177, P633, DOI 10.1001/jamainternmed.2016.9607
  88. Huong NTC, 2022, BMJ OPEN GASTROENTER, V9, DOI 10.1136/bmjgast-2022-000870
  89. Omokaro SO, 2020, ENDOCRIN DIAB METAB, V3, DOI 10.1002/edm2.113
  90. Oni ET, 2013, ATHEROSCLEROSIS, V230, P258, DOI 10.1016/j.atherosclerosis.2013.07.052
  91. Arab JP, 2020, ANN HEPATOL, V19, P674, DOI 10.1016/j.aohep.2020.09.006
  92. Paik JM, 2020, HEPATOLOGY, V72, P1605, DOI 10.1002/hep.31173
  93. Panunzi S, 2021, DIABETES OBES METAB, V23, P980, DOI 10.1111/dom.14304
  94. Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603
  95. Petroff D, 2021, LANCET GASTROENTEROL, V6, P185, DOI 10.1016/S2468-1253(20)30357-5
  96. Petta S, 2021, CLIN GASTROENTEROL H, V19, P806, DOI 10.1016/j.cgh.2020.06.045
  97. Petta S, 2015, HEPATOLOGY, V62, P1101, DOI 10.1002/hep.27844
  98. Polyzos SA, 2019, METABOLISM, V92, P82, DOI 10.1016/j.metabol.2018.11.014
  99. Powell EE, 2021, LANCET, V397, P2212, DOI 10.1016/S0140-6736(20)32511-3
  100. Promrat K, 2010, HEPATOLOGY, V51, P121, DOI 10.1002/hep.23276
  101. Raj H, 2019, WORLD J DIABETES, V10, P114, DOI 10.4239/wjd.v10.i2.114
  102. Saab S, 2014, LIVER INT, V34, P495, DOI 10.1111/liv.12304
  103. Sanyal AJ, 2021, NEW ENGL J MED, V385, P1559, DOI 10.1056/NEJMoa2029349
  104. Sanyal AJ, 2019, HEPATOLOGY, V70, P1913, DOI 10.1002/hep.30664
  105. Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929
  106. Selvaraj EA, 2021, J HEPATOL, V75, P770, DOI 10.1016/j.jhep.2021.04.044
  107. Shen HF, 2014, J GASTROINTEST ONCOL, V5, P440, DOI 10.3978/j.issn.2078-6891.2014.061
  108. Siddiqui MS, 2019, CLIN GASTROENTEROL H, V17, P1877, DOI 10.1016/j.cgh.2018.12.031
  109. Simons N, 2021, AM J CLIN NUTR, V113, P391, DOI 10.1093/ajcn/nqaa332
  110. Singh S, 2015, CLIN GASTROENTEROL H, V13, P643, DOI 10.1016/j.cgh.2014.04.014
  111. Srivastava A, 2019, J HEPATOL, V71, P371, DOI 10.1016/j.jhep.2019.03.033
  112. Stine JG, 2018, ALIMENT PHARM THER, V48, P696, DOI 10.1111/apt.14937
  113. Sun WJ, 2016, HEPATOL RES, V46, P862, DOI 10.1111/hepr.12647
  114. Suzuki K, 2013, HEPATOL RES, V43, P979, DOI 10.1111/hepr.12039
  115. Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063
  116. Tavaglione F, 2022, LIVER INT, V42, P374, DOI 10.1111/liv.15127
  117. Taylor RS, 2020, GASTROENTEROLOGY, V158, P1611, DOI 10.1053/j.gastro.2020.01.043
  118. Ulasoglu C, 2019, J GASTROINTEST LIVER, V28, P427, DOI 10.15403/jgld-293
  119. Vali Y, 2020, J HEPATOL, V73, P252, DOI 10.1016/j.jhep.2020.03.036
  120. van Dam RM, 2020, NEW ENGL J MED, V383, P369, DOI 10.1056/NEJMra1816604
  121. Verma S, 2013, LIVER INT, V33, P1398, DOI 10.1111/liv.12226
  122. Vilar-Gomez E, 2020, HEPATOLOGY, V71, P495, DOI 10.1002/hep.30368
  123. Vilar-Gomez E, 2015, GASTROENTEROLOGY, V149, P367, DOI 10.1053/j.gastro.2015.04.005
  124. Wang H, 2018, BIOMED REP, V9, P90, DOI 10.3892/br.2018.1100
  125. WHO, 2004, LANCET, V363, P902, DOI 10.1016/S0140-6736(03)15268-3
  126. Wijarnpreecha K, 2017, EUR J GASTROEN HEPAT, V29, pE8, DOI 10.1097/MEG.0000000000000776
  127. Winters-van Eekelen E, 2021, EUR J CLIN NUTR, V75, P588, DOI 10.1038/s41430-020-00778-1
  128. Wong VWS, 2019, GUT, V68, P2057, DOI 10.1136/gutjnl-2018-317334
  129. Wu SQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep33386
  130. Xiao GQ, 2017, HEPATOLOGY, V66, P1486, DOI 10.1002/hep.29302
  131. Younossi ZM, 2020, ALIMENT PHARM THER, V52, P513, DOI 10.1111/apt.15830
  132. Younossi ZM, 2019, J HEPATOL, V71, P793, DOI 10.1016/j.jhep.2019.06.021
  133. Younossi ZM, 2018, HEPATOLOGY, V68, P349, DOI 10.1002/hep.29721
  134. Zhang SM, 2022, INT J EPIDEMIOL, V51, P237, DOI 10.1093/ije/dyab174
  135. Zhao HM, 2020, FRONT NUTR, V7, DOI 10.3389/fnut.2020.593735

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT